PLK1 and glioblastoma: In agreement, our findings reveal that tivozanib diminished proliferation of the GBM cells through a G2/M cell cycle arrest via up-regulation of p21 and down-modulation of Aurora kinases A and B, cyclin B1 and CDC25C as well as inhibition of p-PLK1.